403 related articles for article (PubMed ID: 32139020)
41. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
42. Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma.
Beauvais D; Danhof S; Hayden PJ; Einsele H; Yakoub-Agha I
Curr Opin Oncol; 2020 Sep; 32(5):418-426. PubMed ID: 32740095
[TBL] [Abstract][Full Text] [Related]
43. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.
Cohen AD
Am Soc Clin Oncol Educ Book; 2018 May; 38():e6-e15. PubMed ID: 30231373
[TBL] [Abstract][Full Text] [Related]
44. GPRC5D-Directed CAR Yields 100% Response Rate.
Cancer Discov; 2022 Aug; 12(8):OF3. PubMed ID: 35748592
[TBL] [Abstract][Full Text] [Related]
45. Multiple Myeloma, Targeting B-Cell Maturation Antigen With Chimeric Antigen Receptor T-Cells.
Shah UA; Smith EL
Cancer J; 2019; 25(3):208-216. PubMed ID: 31135528
[TBL] [Abstract][Full Text] [Related]
46. Chimeric antigen receptor T cell therapies for multiple myeloma.
Wu C; Zhang L; Brockman QR; Zhan F; Chen L
J Hematol Oncol; 2019 Nov; 12(1):120. PubMed ID: 31752943
[TBL] [Abstract][Full Text] [Related]
47. The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma.
Duan D; Wang K; Wei C; Feng D; Liu Y; He Q; Xu X; Wang C; Zhao S; Lv L; Long J; Lin D; Zhao A; Fang B; Jiang J; Tang S; Gao J
Front Immunol; 2021; 12():609421. PubMed ID: 33767695
[TBL] [Abstract][Full Text] [Related]
48. B-cell maturation antigen-specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives.
Sellner L; Fan F; Giesen N; Schubert ML; Goldschmidt H; Müller-Tidow C; Dreger P; Raab MS; Schmitt M
Int J Cancer; 2020 Oct; 147(8):2029-2041. PubMed ID: 32270481
[TBL] [Abstract][Full Text] [Related]
49. Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma.
García-Guerrero E; Sierro-Martínez B; Pérez-Simón JA
Front Immunol; 2020; 11():1128. PubMed ID: 32582204
[TBL] [Abstract][Full Text] [Related]
50. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
Madduri D; Parekh S; Campbell TB; Neumann F; Petrocca F; Jagannath S
J Med Case Rep; 2021 Feb; 15(1):90. PubMed ID: 33608053
[TBL] [Abstract][Full Text] [Related]
51. Cellular immunotherapy in multiple myeloma.
Vo MC; Lakshmi TJ; Jung SH; Cho D; Park HS; Chu TH; Lee HJ; Kim HJ; Kim SK; Lee JJ
Korean J Intern Med; 2019 Sep; 34(5):954-965. PubMed ID: 30754964
[TBL] [Abstract][Full Text] [Related]
52. Multiple Myeloma: The CAR T-cell Therapy Landscape.
Cancer Discov; 2020 Feb; 10(2):OF6. PubMed ID: 31915196
[TBL] [Abstract][Full Text] [Related]
53. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
Nguyen S; Lacan C; Roos-Weil D
Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
[TBL] [Abstract][Full Text] [Related]
54. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S
Front Immunol; 2018; 9():239. PubMed ID: 29515572
[TBL] [Abstract][Full Text] [Related]
55. BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting.
Wu JF; Dhakal B
J Hematol Oncol; 2023 Jul; 16(1):86. PubMed ID: 37507805
[TBL] [Abstract][Full Text] [Related]
56. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness.
Bachiller M; Perez-Amill L; Battram AM; Carné SC; Najjar A; Verhoeyen E; Juan M; Urbano-Ispizua A; Martin-Antonio B
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34433634
[TBL] [Abstract][Full Text] [Related]
57. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.
Yang J; Zhou W; Li D; Niu T; Wang W
Cancer Lett; 2023 Jan; 553():215949. PubMed ID: 36216149
[TBL] [Abstract][Full Text] [Related]
58. Bench-to-bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic-pharmacodynamic model: A case study with anti-BCMA CAR-T.
Singh AP; Chen W; Zheng X; Mody H; Carpenter TJ; Zong A; Heald DL
CPT Pharmacometrics Syst Pharmacol; 2021 Apr; 10(4):362-376. PubMed ID: 33565700
[TBL] [Abstract][Full Text] [Related]
59. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.
Anderson LD
Future Oncol; 2022 Jan; 18(3):277-289. PubMed ID: 34854741
[TBL] [Abstract][Full Text] [Related]
60. Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.
Choi T; Kang Y
Pharmacol Ther; 2022 Apr; 232():108007. PubMed ID: 34582835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
